HRMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harmony Biosciences Holdings Inc (HRMY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is currently undervalued due to litigation overhang, but analysts and hedge fund activity suggest strong potential upside. Despite short-term risks, the company's growth trajectory, positive litigation developments, and bullish sentiment make it a compelling long-term investment.
The MACD is positively expanding at 0.527, indicating bullish momentum. RSI at 82.154 suggests the stock is overbought, but this is typical during strong uptrends. The stock is trading above key pivot levels (Pivot: 31.195, R1: 33.698), showing strength. Moving averages are converging, signaling potential for further upward movement.
Hedge funds are aggressively buying, with a 18208.08% increase in buying activity last quarter.
Analysts like H.C. Wainwright and Oppenheimer have reiterated Buy/Outperform ratings with price targets of $55 and $72, respectively.
Recent patent litigation developments are seen as positive, boosting investor confidence.
Strong revenue growth of 21.12% YoY in Q4 2025 reflects robust market demand for Wakix.
Litigation risks remain, with potential for generic competition as early as 2026 if patents are lost.
Net income and EPS have declined significantly YoY (-54.55% and -54.12%, respectively).
Some analysts, like Deutsche Bank and BofA, have downgraded the stock with lower price targets, citing patent risks and conservative cash flow projections.
In Q4 2025, revenue increased by 21.12% YoY to $243.78 million, reflecting strong demand for Wakix. However, net income dropped by 54.55% YoY to $22.49 million, and EPS fell by 54.12% YoY to $0.39. Gross margin slightly decreased to 71.88%, down 1.49% YoY.
Analyst sentiment is mixed but leans positive. H.C. Wainwright and Oppenheimer have reiterated Buy/Outperform ratings with price targets of $55 and $72, citing litigation developments and strong market demand. However, Deutsche Bank and BofA have downgraded the stock, citing patent risks and conservative cash flow projections.
